FDA grants emergency authorization to two blood purification systems [MarketWatch]
Marker Therapeutics, Inc. (MRKR)
Last marker therapeutics, inc. earnings: 11/12 04:01 pm
Check Earnings Report
Company Research
Source: MarketWatch
The Food and Drug Administration (FDA) on Friday issued emergency use authorizations to blood purification devices manufactured by Terumo Corp. and Marker Therapeutics Inc. in response to the COVID-19 pandemic. Terumo is a Japanese medical device maker. Marker is a clinical-stage immuno-oncology company based in Houston. An EUA does not mean that that the device has been approved by the FDA; it is an authorization granted during an emergency when there are no other treatment options available. The regulator said that the devices can be used for adult patients with COVID-19 who are being cared for in the intensive care unit and have confirmed or imminent respiratory failure to reduce the amount of cytokines in those patients. Some severely ill COVID-19 patients have had "cytokine storms" that can lead to organ failure and death. Year-to-date, Terumo's stock is down 3.9%, while shares of Marker have dropped 39.2%. The S&P 500 has dropped 13.6% since the beginning of 2020.
Show less
Read more
Impact Snapshot
Event Time:
MRKR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRKR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRKR alerts
High impacting Marker Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
MRKR
News
- Marker Therapeutics, Inc. (NASDAQ: MRKR) is now covered by analysts at LADENBURG THALM/SH SH. They set a "buy" rating and a $11.00 price target on the stock.MarketBeat
- Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies [Yahoo! Finance]Yahoo! Finance
- Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies GlobeNewswire
- Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results [Yahoo! Finance]Yahoo! Finance
- Marker Therapeutics Reports Year-End 2023 Corporate and Financial ResultsGlobeNewswire
MRKR
Sec Filings
- 4/26/24 - Form ARS
- 4/26/24 - Form DEF
- 4/8/24 - Form 8-K
- MRKR's page on the SEC website